Source: Company's LinkedIn profile

Viome, a Washington based gut health startup, has raised USD 54 million in a pre-series C convertible funding round from Ocgrow Ventures and many existing investors on 10 November 2021. This round brings Viome’s total raised funds to over USD 125 million.

Investors: New investor, Ocgrow Ventures and existing investors including Khosla Ventures, WestRiver Group, Glico, Physician Partners and Bold Capital Partners contributed to the latest funding round. Harish Consul, Founder and CEO of Ocgrow Ventures, will become a board observer for the startup.

The Objectives behind the funding: The company plans to deploy the current proceeds to research aggressive cancers and chronic diseases and, ideally, come up with early-stage diagnostics and therapeutics for those ailments. The company digitizes the human body and its microbiomes on a molecular level using at home clinical-grade tests, analyzed through proprietary RNA sequencing technology, and decodes precise health insights and biomarkers of various chronic diseases using artificial intelligence and systems biology expertise. It enables healthcare providers to give personalized nutrition recommendations and precision supplements to their patients.

About Viome

Source: Company’s LinkedIn profile

Founded in 2016 by Deepak Savadatti, Momchilo Vuyisich and Naveen Jain, Viome  is a provider of comprehensive health insights designed to help people track their microbiome health, mitochondrial health, cellular health, and biological age. The company recently relocated its laboratory operations to a 25,000-square-foot location in Bothell, Washington, that has given Viome space to grow its capacity and expand to 15 new countries (Australia, Belgium, Cyprus, Denmark, Estonia, Finland, Greece, Hungary, Iceland, Ireland, Italy, Poland, Portugal, Spain and Sweden). It is currently able to get test results back to customers within two weeks. Now, the company is focused more on its work to advance its mRNA technology and AI platform as well as its partnership with biopharma company GSK to conduct clinical trials and develop therapeutics to target health issues like Alzheimer’s disease, metabolic diseases and mental health conditions. 

What the Founder has to say:

Viome founder and CEO Naveen Jain hopes one day the platform can help detect a long list of cancers in their earliest stages, including pancreatic, bile, breast, head, neck and shoulder cancers, among others.

“We thought ‘What are the diseases that we can diagnose early, where we can have a significant impact on humanity?’” Naveen Jain, Founder and CEO of Viome, said in a recent interview. “Obviously, cancer is one of those. I lost my dad to cancer, so it was really meaningful to me to be able to do something about it.” 

What the Investor has to say:

The startup’s work will “help solve the root causes of so many chronic diseases to benefit all humanity,” Harish Consul, Founder and CEO of Ocgrow Ventures, said in a statement. “Viome is rapidly scaling to become a global leader in the longevity space to promote better health outcomes today and for our future generations with exceptional innovation.”  

For more extensive analysis and Market Intelligence reports feel free to approach us or visit our website: Venture Capital Market Intelligence Reports | VCBay.

We try our best to fact check and bring the best, well-researched and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!

Next Article

Previous articleUS-based Socure raises USD 450 million in series E round
Next articleUS-based startup Daily secures US$ 40M in Series B funding
Manish writes about the startup ecosystem on VCBay. He is pursuing Master of Commerce from Delhi School of Economics, University of Delhi, and is passionate about the world of finance, information technology & entrepreneurship.



Please enter your comment!
Please enter your name here